Compare Gemini Space Station Inc (GEMI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Sana Biotechnology Inc — how do they compare? Gemini Space Station Inc trades at $4.4 (market cap $579.55M), while Sana Biotechnology Inc trades at $2.81 (market cap $836.71M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and Sana Biotechnology Inc is more actively traded (4,507,444 versus 1,882,406). Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and Sana Biotechnology Inc for 23 Days on average.
| GEMI | SANA | |
|---|---|---|
Market Cap | $579.55M | $836.71M |
Volume | 1,882,406 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $25.41 | $5.92 |
52-Week Low | $3.54 | $2.68 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $558.57M | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.40, down 2% today amid bearish technical signals and persistent financial losses. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings expectations with a net loss of -$0.89 per share. Despite expanding services revenue and new product offerings, negative profit margins and cash flow challenges persist. Technical indicators show oversold conditions with RSI readings below 11, while moving averages signal continued downward pressure.
The stock faces significant fundamental headwinds with negative margins and cash burn, though analyst consensus suggests 19% upside to the $5.25 price target. Key risks include ongoing litigation, competitive pressures in financial services, and the company's ability to achieve profitability. Recent SEC approval for tokenized stock trading could provide growth opportunities if execution improves.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
